Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan March 11, 2026 Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually.
Wilson James Selects Legion’s AI-Powered Workforce Management Platform to Transform Workforce Operations March 10, 2026 Wilson James, a leading integrated solutions provider operating across aviation, security, infrastructure, and logistics, has selected Legion’s AI-powered Workforce Management (WFM) platform as part of a strategic transformation to redefine how complex, people-led operations are planned, managed, and optimised across its UK and international divisions. Operating in some of the most demanding and highly regulated [...]
Bregal Sphere and Imperative Partner With Ambition to Deploy up to $500 Million Into Global Nature Restoration Projects March 10, 2026 Bregal Sphere, part of Bregal Investments, today announced a strategic partnership with Imperative, providing financing to accelerate the development of its global pipeline of high-quality ecosystem restoration projects. As a leading institutional natural capital investor, Bregal Sphere partners with best-in-class developers to deliver large-scale carbon removal projects that generate meaningful impacts for nature, climate, and [...]
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology March 10, 2026 C-Further to advance its first two bespoke paediatric cancer therapeutics in collaboration with leading global academic and industry investigators Selected programmes to potentially address multiple children’s cancers including Ewing sarcoma, bone sarcoma, medulloblastoma and acute myeloid leukaemia Additional C-Further programmes to be announced in 2026
Amentum-led Joint Venture selected for $112 Million Clean-up at Four European Nuclear Research Sites March 10, 2026 A joint venture led by Amentum (NYSE: AMTM) has won a new framework contract as the lead decommissioning and waste management contractor for nuclear research sites in four European countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310491705/en/ Under the $112 million (€95.7 million) contract, awarded by the European Commission Joint Research [...]
VIPR Announces Strategic Engagement with Aon to Transform Delegated Authority Operations March 10, 2026 Multi-year engagement to deliver intelligent automation and operational clarity across global reinsurance platform
Operio Group Named Distributor for Schaefer Technologies in the United Kingdom and European Union March 9, 2026 Operio Group has signed a distribution agreement with Schaefer Technologies, a manufacturer of semi-automatic encapsulation equipment. Operio Group, a holding company building a global group of brands serving the solid dose manufacturing industry, will be the official distributor of Schaefer Technologies’ products in the United Kingdom and the European Union. Schaefer Technologies develops semi-automatic capsule [...]
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy March 9, 2026 Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk
ABB Robotics Partners with NVIDIA to Deliver Industrial-Grade Physical AI at Scale March 9, 2026 ABB Robotics integrates NVIDIA Omniverse libraries into RobotStudio® to deliver physical AI for industry, closing the gap from virtual training to real-world deployment with up to 99% accuracy New RobotStudio HyperReality, available second half of 2026, will fundamentally change how quickly and reliably manufacturers can scale production, reducing costs by up to 40% and accelerating time-to-market by 50% Full range and breadth of industrial applications, with real-world pilot being conducted by Foxconn in consumer electronics assembly At NVIDIA GTC, the robotic workforce company WORKR will showcase how it’s using the solution to help manufacturers across the U.S. addressing critical labor shortages
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG March 6, 2026 Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI [...]